| 引用本文: | 郑琳,代晓阳,张燕,董晓武,翁勤洁.新型AKT抑制剂Hu7691对胃癌细胞的抗肿瘤活性及机制研究[J].中国现代应用药学,2021,38(16):1921-1927. |
| ZHENG Lin,DAI Xiaoyang,ZHANG Yan,DONG Xiaowu,WENG Qinjie.Anti-cancer Efficacy Against Gastric Cancer Cells and Mechanism Study of a Novel AKT Inhibitor Hu7691[J].Chin J Mod Appl Pharm(中国现代应用药学),2021,38(16):1921-1927. |
|
| 本文已被：浏览 1833次 下载 890次 |
码上扫一扫！ |
|
|
| 新型AKT抑制剂Hu7691对胃癌细胞的抗肿瘤活性及机制研究 |
|
郑琳1,2, 代晓阳1,2, 张燕1,2, 董晓武1,2, 翁勤洁1,2
|
|
1.浙江大学, 药学院, 杭州 310058;2.浙江大学, 药物安全评价研究中心, 杭州 310058
|
|
| 摘要: |
| 目的 考察新型AKT抑制剂Hu7691对胃癌细胞的体内外抗肿瘤活性及作用机制。方法 以人胃癌细胞HGC27和BGC823为体外细胞模型，采用SRB法评价不同浓度的Hu7691对胃癌细胞的体外增殖抑制作用；以流式细胞术考察Hu7691对HGC27细胞周期的影响，采用Western blotting考察Hu7691作用后，细胞内相关蛋白的表达变化；采用HGC27裸小鼠移植瘤模型评价Hu7691的体内抗肿瘤活性。结果 Hu7691在HGC27和BGC823细胞模型上能显著抑制肿瘤细胞增殖；引起肿瘤细胞发生细胞周期阻滞，浓度依赖性地下调AKT通路相关蛋白p-PRAS40（T246）、p-GSK3β、p-S6（S235/236）、p-4EBP1（T37/46）及p-4EBP1（S65）的蛋白表达，上调p-AKT （S473）、p-AKT （S308）的表达；下调细胞周期相关蛋白Cyclin D1的表达；在HGC27裸小鼠移植瘤模型中，Hu7691能显著抑制肿瘤生长，并且对小鼠体质量无显著影响。结论 新型AKT抑制剂Hu7691通过诱导细胞周期阻滞，发挥对胃癌细胞体内外显著的抗肿瘤活性。 |
| 关键词: AKT抑制剂 Hu7691 胃癌 抗肿瘤活性 周期阻滞 |
| DOI：10.13748/j.cnki.issn1007-7693.2021.16.001 |
| 分类号:R965.1 |
| 基金项目:中国博士后科学基金面上项目（2020M671766） |
|
| Anti-cancer Efficacy Against Gastric Cancer Cells and Mechanism Study of a Novel AKT Inhibitor Hu7691 |
|
ZHENG Lin1,2, DAI Xiaoyang1,2, ZHANG Yan1,2, DONG Xiaowu1,2, WENG Qinjie1,2
|
|
1.Zhejiang University, College of Pharmaceutical Sciences, Hangzhou 310058, China;2.Zhejiang University, Center for Drug Safety Evaluation and Research, Hangzhou 310058, China
|
| Abstract: |
| OBJECTIVE To investigate the anti-cancer efficacy of a novel AKT inhibitor Hu7691 against gastric cancer cells and its mechanism. METHODS Using human gastric cancer cells HGC27 and BGC823 as in vitro cell models, the SRB method was used to evaluate the in vitro proliferation inhibitory effects of Hu7691 at different concentrations on gastric cancer. The effect of Hu7691 on cell cycle was detected by flow cytometry. Western blotting was performed to determine the change of protein level caused by Hu7691 treatment. The in vivo anti-tumor efficacy was assessed in a human HGC27 gastric cancer xenograft model. RESULTS Hu7691 exhibited significant cytotoxicity in gastric cancer HGC27 and BGC823 cells and induced cell cycle arrest. Hu7691 treatment downregulated the protein expression of AKT pathway related proteins of p-PRAS40(T246), p-GSK3β, p-S6(S235/236), p-4EBP1(T37/46) and p-4EBP1(S65) in a concentration-dependent manner, while it upregulated the expression of p-AKT(S473) and p-AKT(S308), down-regulated the expression of cell cycle related protein Cyclin D1. The anti-cancer efficacy of Hu7691 was validated in the HGC27 xenograft model and had no significant effect on the body weight of the mice. CONCLUSION The novel AKT inhibitor Hu7691 exhibits potent in vitro and in vivo anti-caner efficacy on gastric cancer cells via inducing cell cycle arrest. |
| Key words: AKT inhibitor Hu7691 gastric cancer anti-cancer efficacy cell cycle arrest |
